Immunity and inflammation in neurodegenerative diseases

American Journal of Neurodegenerative Diseases

Volumn 2, Issue 2, 2013, Pages 89-107

  Cappellano, Giuseppe ^a   Carecchio, Miryam ^b   Fleetwood, Thomas ^b   Magistrelli, Luca ^b   Cantello, Roberto ^b   Dianzani, Umberto ^a   Comi, Cristoforo ^a,b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Amedeo Avogadro University   (Italy)

Author keywords

Alzheimer s disease; Multiple sclerosis; Neuro immnue interactions; Neuroinflammation; Parkinsons disease

Indexed keywords

ALPHA SYNUCLEIN; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BHT 3009; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTADHERIN; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEIN; OSTEOPONTIN; PEPTIDE VACCINE; PROTEIN S100B; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALZHEIMER DISEASE; CELL DIFFERENTIATION; CELL MIGRATION; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DOWN REGULATION; DRUG EFFICACY; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; MEMBRANE MICROPARTICLE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 84980052308     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Review

References (182)

1. Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest 2012; 122: 1164-7.
2. Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. Neuro Rx 2005; 2: 86-98.
3. Poller B, Drewe J, Krähenbühl S, Huwyler J, Gutmann H. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol 2010; 30: 63-70.
4. DeSalvo MK, Mayer N, Mayer F, Bainton RJ. Physiologic and anatomic characterization of the brain surface glia barrier of Drosophila. Glia 2011; 59: 1322-40.
5. Weller RO, Galea I, Carare RO, Minagar A. Pathophysiology of the lymphatic drainage of the central nervous system: Implications for pathoge-nesis and therapy of multiple sclerosis. Pathophysiology 2010; 17: 295-306.
6. Satpathy AT, Wu X, Albring JC, Murphy KM. Re(de)fining the dendritic cell lineage. Nat Immunol 2012; 13: 1145-54.
7. Förster R, Braun A, Worbs T. Lymph node homing of T cells and dendritic cells via afferent lymphatics. Trends Immunol 2012; 33: 271- 80.
8. Dudda JC, Lembo A, Bachtanian E, Huehn J, Siewert C, Hamann A, Kremmer E, Förster R, Martin SF. Dendritic cells govern induction and reprogramming of polarized tissue-selective homing receptor patterns of T cells: important roles for soluble factors and tissue microenvironments. Eur J Immunol 2005; 35: 1056-65.
9. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol 2007; 28: 12-8.
10. Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 2007; 184: 37-44.
11. Dobolyi A, Vincze C, Pál G, Lovas G. The neuroprotective functions of transforming growth factor Beta proteins. Int J Mol Sci 2012; 13: 8219-58.
12. Strle K, Zhou JH, Shen WH, Broussard SR, Johnson RW, Freund GG, Dantzer R, Kelley KW. Interleukin-10 in the brain. Crit Rev Immunol 2001; 21: 427-49.
13. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28: 254-60.
14. Owens T, Bechmann I, Engelhardt B. Perivascular spaces and the two steps to neuroinflammation. J Neuropatol Exp Neurol 2008; 67: 1113-21.
15. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19: 312-8.
16. Raivich G, Bluethmann H, Kreutzberg GW. Signaling molecules and neuroglial activation in the injured central nervous system. Keio J Med 1996; 45: 239-47.
17. Butovsky O, Bukshpan S, Kunis G, Jung S, Schwartz M. Microglia can be induced by IFNgamma or IL-4 to express neural or dendriticlike markers. Mol Cell Neurosci 2007; 35: 490- 500.
18. Polazzi E, Monti B. Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog Neurobiol 2010 Nov; 92: 293- 315.
19. Shaked I, Tchoresh D, Gersner R, Meiri G, Mordechai S, Xiao X, Hart RP, Schwartz M. Protective autoimmunity: interferon-gamma enables microglia to remove glutamate without evoking inflammatory mediators. J Neurochem 2005; 92: 997-1009.
20. Luo XG, Chen SD. The changing phenotype of microglia from homeostasis to disease. Transl Neurodegener 2012; 1: 9.
21. Graber JJ, Ghib-Jalbut S. Protective autoimmunity in nervous system. Pharmacol Ther 2009; 121: 147-159.
22. Luo XG, Chen SD. The changing phenotype of microglia from homeostasis to disease. Transl Neurodegener 2012 Apr 24; 1: 9.
23. Piehl F, Lidman O. Neuroinflammation in the rat--CNS cells and their role in the regulation of immune reactions. Immunol Rev 2001; 184: 212-25.
24. Trajkovic V, Vuckovic O, Stosic-Grujicic S, Miljkovic D, Popadic D, Markovic M, Bumbasirevic V, Backovic A, Cvetkovic I, Harhaji L, Ramic Z, Mostarica Stojkovic M. Astrocyte-induced regulatory T cells mitigate CNS autoimmunity. Glia 2004; 47: 168-79.
25. Li J, Gran B, Zhang GX, Ventura ES, Siglienti I, Rostami A, Kamoun M. Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. J Neurol Sci 2003; 215: 95-103.
26. Lukens JR, Barr MJ, Chaplin DD, Chi H, Kanneganti TD. Inflammasome-derived IL-1β regulates the production of GM-CSF by CD4(+) T cells and γδ T cells. J Immunol 2012; 188: 3107-15.
27. Schwartz M, London A, Shechter R. Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: the role of innate immunity. Neuroscience 2009; 158: 1133-1142.
28. O'Callaghan JP, Sriram K, Miller DB. Defining "neuroinflammation". Ann N Y Acad Sci 2008; 1139: 318-30.
29. Zettl UK, Stüve O, Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 2012; 11: 167-173.
30. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995; 1: 119-146.
31. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol 2012; 142: 2-8.
32. Owens GP, Bennett JL. Trigger, pathogen, or bystander: the complex nexus linking Epstein- Barr virus and multiple sclerosis. Mult Scler 2012; 18: 1204-8.
33. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006; 19: 80-94.
34. Odoardi F, Sie C, Streyl K, Ulaganathan VK, Schläger C, Lodygin D, Heckelsmiller K, Nietfeld W, Ellwart J, Klinkert WE, Lottaz C, Nosov M, Brinkmann V, Spang R, Lehrach H, Vingron M, Wekerle H, Flügel-Koch C, Flügel A. T cells become licensed in the lung to enter the central nervous system. Nature 2012; 488: 675- 9.
35. Khoshnam M, Freedman MS. Disease-specific therapy of idiopathic inflammatory demyelinating disorders. Expert Rev Neurother 2012; 12: 1113-24.
36. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001; 14: 271-8.
37. Huizinga R, Linington C, Amor S. Resistance is futile: antineuronal autoimmunity in multiple sclerosis. Trends Immunol 2008; 29: 54-60.
38. Tsunoda I, Fujinami RS. Inside-Out versus Outside- In models for virus induced demyelination: axonal damage triggering demyelination. Springer Semin Immunopathol 2002; 24: 105- 25.
39. Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, Compston A, Franklin RJ, Baker D, Chandran S. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol 2008; 201-202: 200-11.
40. Huizinga R, Heijmans N, Schubert P, Gschmeissner S, 't Hart BA, Herrmann H, Amor S. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J Neuropathol Exp Neurol 2007; 66: 295-304.
41. Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G, FIlippi M. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol 2002; 1: 499-509.
42. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37: 424-35.
43. Comi C, Fleetwood T, Dianzani U. The role of T cell apoptosis in nervous system autoimmunity. Autoimmun Rev 2012; 12: 150-6.
44. Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas Navarro J, Río J, Montalban X. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005; 158: 231-9.
45. Vogt MH, Floris S, Killestein J, Knol DL, Smits M, Barkhof F, Polman CH, Nagelkerken L. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 2004; 155: 155-60.
46. Chiocchetti A, Comi C, Indelicato M, Castelli L, Mesturini R, Bensi T, Mazzarino MC, Giordano M, D'Alfonso S, Momigliano-Richiardi P, Liguori M, Zorzon M, Amoroso A, Trojano M, Monaco F, Leone M, Magnani C, Dianzani U. Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. J Neuroimmunol 2005; 163: 172-178.
47. Comi C, Cappellano G, Chiocchetti A, Orilieri E, Buttini S, Ghezzi L, Galimberti D, Guerini F, Barizzone N, Perla F, Leone M, D'Alfonso S, Caputo D, Scarpini E, Cantello R, Dianzani U. The impact of osteopontin gene variations on multiple sclerosis development and progression. Clin Dev Immunol 2012; 2012: 212893.
48. Burns JB, Bartholomew BD, Lobo ST. In vivo activation of myelin oligodendrocyte glycoproteinspecific T cells in healthy control subjects. Clin Immunol 2002; 105: 185-91.
49. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M, Schröder R, Deckert M, Schmidt S, Ravid R, Rajewsky K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192: 393-404.
50. Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002; 25: 313-9.
51. Vergelli M, Hemmer B, Muraro PA, Tranquill L, Biddison WE, Sarin A, McFarland HF, Martin R. Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. J Immunol 1997; 158: 2756-2761.
52. Rubesa G, Podack ER, Sepcic J, Rukavina D. Increased perforin expression in multiple sclerosis patients during exacerbation of disease in peripheral blood lymphocytes. J Neuroimmunol 1997; 74: 198-204.
53. Murray PD, McGavern DB, Lin X, Njenga MK, Leibowitz J, Pease LR, Rodriguez M. Perforindependent neurologic injury in a viral model of multiple sclerosis. J Neurosci 1998; 18: 7306- 7314.
54. Howe CL, Adelson JD, Rodriguez M. Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis 2007; 25: 354-9.
55. Hoffmann O, Zipp F, Weber JR. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation. J Mol Med (Berl) 2009; 87: 753-63.
56. Cappellano G, Orilieri E, Comi C, Chiocchetti A, Bocca S, Boggio E, Bernardone IS, Cometa A, Clementi R, Barizzone N, D'Alfonso S, Corrado L, Galimberti D, Scarpini E, Guerini FR, Caputo D, Paolicelli D, Trojano M, Figà-Talamanca L, Salvetti M, Perla F, Leone M, Monaco F, Dianzani U. Variations of the perforin gene in patients with multiple sclerosis. Genes Immun 2008; 9: 438-44.
57. Comi C, Leone M, Bonissoni S, DeFranco S, Bottarel F, Mezzatesta C, Chiocchetti A, Perla F, Monaco F, Dianzani U. Defective T cell fas function in patients with multiple sclerosis. Neurology 2000; 55: 921-7.
58. Dianzani U, Chiocchetti A, Ramenghi U. Role of inherited defects decreasing Fas function in autoimmunity. Life Sci 2003; 72: 2803-24.
59. Ramenghi U, Bonissoni S, Migliaretti G, De- Franco S, Bottarel F, Gambaruto C, DiFranco D, Priori R, Conti F, Dianzani I, Valesini G, Merletti F, Dianzani U. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of au-toimmune diseases and cancer. Blood 2000; 95: 3176-82.
60. DeFranco S, Bonissoni S, Cerutti F, Bona G, Bottarel F, Cadario F, Brusco A, Loffredo G, Rabbone I, Corrias A, Pignata C, Ramenghi U, Dianzani U. Defective function of Fas in patients with type 1 diabetes associated with other autoimmune diseases. Diabetes 2001; 50: 483-8.
61. Clementi R, Dagna L, Dianzani U, Dupré L, Dianzani I, Ponzoni M, Cometa A, Chiocchetti A, Sabbadini MG, Rugarli C, Ciceri F, Maccario R, Locatelli F, Danesino C, Ferrarini M, Bregni M. Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. N Engl J Med 2004; 351: 1419-24.
62. Clementi R, Chiocchetti A, Cappellano G, Cerutti E, Ferretti M, Orilieri E, Dianzani I, Ferrarini M, Bregni M, Danesino C, Bozzi V, Putti MC, Cerutti F, Cometa A, Locatelli F, Maccario R, Ramenghi U, Dianzani U. Variations of the perforin gene in patients with autoimmuni-ty/lymphoproliferation and defective Fas function. Blood 2006; 108: 3079-84.
63. Orilieri E, Cappellano G, Clementi R, Cometa A, Ferretti M, Cerutti E, Cadario F, Martinetti M, Larizza D, Calcaterra V, D'Annunzio G, Lorini R, Cerutti F, Bruno G, Chiocchetti A, Dianzani U. Variations of the perforin gene in patients with type 1 diabetes. Diabetes 2008; 57: 1078-83.
64. McLaughlin KA, Wucherpfennig KW. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 2008; 98: 121-49.
65. Elkarim RA, Mustafa M, Kivisäkk P, Link H, Bakhiet M. Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. Eur J Clin Invest 1998; 28: 295-299.
66. Cappellano G, Orilieri E, Woldetsadik AD, Boggio E, Soluri MF, Comi C, Sbalttero D, Chiocchetti A, Dianzani U. Anti-cytokine autoantibodies in autoimmune diseases. Am J Clin Exp Immunol 2012; 1: 136-146.
67. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52: 61-76.
68. Brynedal B, Duvefelt K, Jonasdottir G, Roos IM, Akesson E, Palmgren J, Hillert J. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One 2007 Jul 25; 2: e664.
69. Baranzini SE, Nickles D. Genetics of multiple sclerosis: swimming in an ocean of data. Curr Opin Neurol 2012; 25: 239-45.
70. Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med (Berl) 1997; 75: 77-88.
71. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001; 2: 762-64.
72. Tsunoda I, Kuang LQ, Theil DJ, Fujinami RS. Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains. Brain Pathol 2000; 10: 402-18.
73. Verderio C, Muzio L, Turola E, Bergami A, Novellino L, Ruffini F, Riganti L, Corradini I, Francolini M, Garzetti L, Maiorino C, Servida F, Vercelli A, Rocca M, Dalla Libera D, Martinelli V, Comi G, Martino G, Matteoli M, Furlan R. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol 2012; 72: 610-24.
74. Colombo E, Borgiani B, Verderio C, Furlan R. Microvesicles: novel biomarkers for neurological disorders. Front Physiol 2012; 3: 63.
75. Watzlawik J, Warrington AE, Rodriguez M. Importance of oligodendrocyte protection, blood brain barrier breakdown and inflammation for remyelination. Expert Rev Neurother 2010; 10: 441-457.
76. Windrem MS, Roy NS, Wang J, Nunes M, Benraiss A, Goodman R, McKhann GM 2nd, Goldman SA. Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the rat brain. J Neurosci Res 2002; 69: 966-75.
77. Miron VE, Kuhlmann T, Antel JP. Cells of the oligodendroglial lineage, myelination, and remyelination. Biochim Biophys Acta 2011; 1812: 184-93.
78. Patel JR, Klein RS. Mediators of oligodendrocyte differentiation during remyelination. FEBS Lett 2011; 585: 3730-7.
79. Bruce CC, Zhao C, Franklin RJ. Remyelination- An effective means of neuroprotection. Horm Behav 2010; 57: 56-62.
80. Kotter MR, Li WW, Zhao C, Franklin RJ. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci 2006; 26: 328-32.
81. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999; 122: 2279-95.
82. Bieber AJ, Kerr S, Rodriguez M. Efficient Central Nervous System Remyelination Requires T Cells. Ann Neurol 2003; 53: 680-684.
83. Hohlfeld R, Kerschensteiner M, Stadelmannc C, Lassmannc H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 2000; 17: 161-166.
84. Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol 2002; 132: 180-188.
85. De Santi L, Annunziata P, Sessa E, Bramanti P. Brain-derived neurotrophic factor and Trk receptor in experimental autoimmune encephalo- myelitis and multiple sclerosis. J Neurol Sci 2009; 287: 17-26.
86. Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S, Svenningsson A, Lindå H, van Der Meide PH, Cullheim S, Olsson T, Piehl F. Neuroprotection by Encephalomyielitis. Rescue of Mechanically Injured Neurons and Neurotrophin Production by CNSInfiltrating T and Natural Killer Cells. J Neurosci 2000; 20: 5283-5291.
87. Kalinowska-Łyszczarz A, Pawlak MA, Michalak S, Paprzycki W, Losy J. Immune cell NT-3 expression is associated with brain atrophy in multiple sclerosis patients. J Neuroimmunol 2011; 240-241: 109-13.
88. Rivera VM. Tovaxin for multiple sclerosis. Expert Opin Biol Ther 2001; 11: 961-967.
89. Garren H. A DNA vaccine for multiple sclerosis. Expert Opin Biol Ther 2008; 8: 1539-1550.
90. Fissolo N, Montalban X, Comabella M. DNAbased vaccines for multiple sclerosis: current status and future directions. Clin Immunol 2012; 142: 76-83.
91. Correale J, Lund B, McMillan M, Ko DY, McCarthy K, Weiner LP. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 2000; 107: 130-9.
92. Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 2007; 64: 1407-1415.
93. Mannie MD, Blanchfield JL, Islam SM, Abbott DJ. Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis. Front Immunol 2012; 3: 255.
94. Mokhtarian F, Safavi F, Sarafraz-Yazdi E. Immunization with a peptide of Semliki Forest virus promotes remyelination in experimental autoimmune encephalomyelitis. Brain Res 2012; 1488: 92-103.
95. Fissolo N, Costa C, Nurtdinov RN, Bustamante MF, Liombart V, Mansilla MJ, Espejo C, Montalban X, Comabella M. Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental auto-immune encephalomyelitis. J Neuroinflammation 2012; 9: 139.
96. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997; 275: 630-631.
97. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
98. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61: 1013-21.
99. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010; 129: 154-69.
100. Lotz M, Ebert S, Esselmann H, Iliev AI, Prinz M, Wiazewicz N, Wiltfang J, Gerber J, Nau R. Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. J Neurochem 2005; 94: 289-98.
101. Udan ML, Ajit D, Crouse NR, Nichols MR. Tolllike receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J Neurochem 2008; 104: 524-33.
102. Mandrekar S, Jiang Q, Lee CYD, Koenigsknecht- Talboo J, Holtzman DM, Landreth GE. Microglia mediate the clearance of soluble Aβ through fluide phase macropinocytosis. J Neurosci 2009; 29: 4252-4262.
103. Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci 2004; 24: 9838-9846.
104. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV. Clearance of amyloidbeta by circulating lipoprotein receptors. Nat Med 2007; 13: 1029-1031.
105. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J. Adult mouse astrocytes degrade amyloid-β in vitro and in situ. Nat Med 2003; 4: 453-457.
106. Hinojosa AE, Garcia-Bueno B, Leza JC, Madrigal JL. CCL2/MCP-1 modulation of microglial activation and proliferation. J Neuroinflammation 2011; 8: 77.
107. Jaeger PA, Pickford F, Sun CH, Lucin KM, Masliah E, Wyss-Coray T. Regulation of amyloid precursor protein processing by the Beclin 1 complex. PLoS One 2010; 5: e11102.
108. Galimberti D, Fenoglio C, Scarpini E. Inflammation in neurodegenerative disorders: friend or foe? Curr Aging Sci 2008; 1: 30-41.
109. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, Moss T, Griffin WS. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000; 47: 365-8.
110. Forloni G, Demicheli F, Giorgi S, Bendotti C, Angeretti N. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Brain Res Mol Brain Res 1992; 16: 128-34.
111. Löffler J, Huber G. Beta-amyloid precursor protein isoforms in various rat brain regions and during brain development. J Neurochem 1992; 59: 1316-24.
112. Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr 2006; 83: 470S- 474S.
113. Graham DI, Gentleman SM, Nicoll JA, Royston MC, McKenzie JE, Roberts GW, Griffin WS. Altered beta-APP metabolism after head injury and its relationship to the aetiology of Alzheimer's disease. Acta Neurochir Suppl 1996; 66: 96-102.
114. Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WS. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 1996; 17: 761-6.
115. Sheng JG, Jones RA, Zhou XQ, McGinness JM, Van Eldik LJ, Mrak RE, Griffin WS. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem Int 2001; 39: 341-8.
116. Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE, Griffin WS. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 2000; 20: 149-55.
117. Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55: 273-9.
118. Li Y, Wang J, Sheng JG, Liu L, Barger SW, Jones RA, Van Eldik LJ, Mrak RE, Griffin WS. S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J Neurochem 1998; 71: 1421- 8.
119. Liu L, Li Y, Van Eldik LJ, Griffin WS, Barger SW. S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific tran-scription factors. J Neurochem 2005; 92: 546-53.
120. Li Y, Barger SW, Liu L, Mrak RE, Griffin WS. S100beta induction of the proinflammatory cytokine interleukin-6 in neurons. J Neurochem 2000; 74: 143-50.
121. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004; 61: 668-72.
122. Schram MT, Euser SM, de Craen AJ, Witteman JC, Frölich M, Hofman A, Jolles J, Breteler MM, Westendorp RG. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 2007; 55: 708-16.
123. Comi C, Carecchio M, Chiocchetti A, Nicola S, Galimberti D, Fenoglio C, Cappellano G, Monaco F, Scarpini E, Dianzani U. Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline. J Alzheimers Dis 2010; 19: 1143-8.
124. Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, Cole G, Sokolow S, Gylys K, Geschwind DH, Cummings JL, Wan HI. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol 2012; 69: 96-104.
125. Mineur YS, McLoughlin D, Crusio WE, Sluyter F. Genetic mouse models of Alzheimer's disease. Neural Plast 2005; 12: 299-310.
126. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM. Blocking IL-1 signaling rescues cognition, atte-nuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol 2011; 187: 6539-49.
127. Boissennealut V, Filali M, Lessard N, Relton J, Wong G, Rivest S. Powerful beneficial effects of macrophage colony-stimulating factor on β-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 2009; 132: 1078-1092.
128. Ray S, Britschgi M, Herbet C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-1362.
129. Mizuno T, Doi Y, Mizoguchi H, Jin S, Noda M, Sonobe Y, Takeuchi H, Suzumura A. Interleukin- 34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity. Am J Pathol 2011; 179: 2016-27.
130. Sang M, Jin J, Lim JE, Kou J, Pattanayak A, Rehman JA. TLR4 mutation reduces microglial activation, increases Ab deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation 2011; 8: 92.
131. Fuller AD, Van Eldik LJ. MFG-E8 regulates microglial phagocytosis of apoptotic neurons. J Neuroimmune Pharmacol 2008; 3: 246-56.
132. Boddaert J, Kinugawa K, Lambert JC, Boukhtouche F, Zoll J, Merval E, Blanc-Brude O, Mann D, Berr C, Vilar J, Garabedian B, Journiac N, Charue D, Silvestre JS, Duyckaerts C, Amouyel P, Mariani J, Tedgui A, Mallat Z. Evidence of a Role for Lactadherin in Alzheimer's Disease. Am J Pathol 2007; 190: 921-929.
133. van Beek J, Elward K, Gasque P. Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci 2003; 992: 56-71.
134. Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000; 49: 171-86.
135. Thomas A, Gasque P, Vaudry D, Gonzalez B, Fontaine M. Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol 2000; 12: 1015-23.
136. Gasque P, Singhrao SK, Neal JW, Götze O, Morgan BP. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 1997; 150: 31-41.
137. Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M, Morgan BP. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 1998; 160: 3543-54.
138. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol 1982; 57: 239-42.
139. O'Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, Cooper NR. Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 2001; 166: 4154-62.
140. Kulkarni AP, Kellaway LA, Lahiri DK, Kotwal GJ. Neuroprotection from complement-mediated inflammatory damage. NY Acad Sci 2004; 1035: 147-164.
141. Wyss-Coray T, Yan F, Hsiu-Ti Li A, Lambris JD, Alexander JJ, Quigg RJ, Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. PNAS 2002; 16: 10837-10842.
142. Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Complement Component C1q Modulates the Phagocytosis of Ab by Microglia. Exp Neurol 2000; 161: 127- 138.
143. Benoit ME, Hernandez MX, Dinh ML, Benavente F, Vasquez O, Tenner AJ. C1q-induced LRP1B and GPR6 Proteins Expressed Early in Alzheimer Disease Mouse Models, are essential for the C1qmediated Protection against Amyloid-β Neurotoxicity. J Biol Chem 2013; 288: 654- 665.
144. Cribbs DH. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets 2010; 9: 207-216.
145. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med 2010; 220: 95-106.
146. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebocontrolled phase I trial. Lancet 2008; 372: 216-23.
147. Galimberti D, Ghezzi L, Scarpini E. Immunotherapy against amyloid pathology in Alzheimer's disease. J Neurol Sci 2013; [Epub ahead of print].
148. Bi M, Ittner A, Ke YD, Götz J, Ittner LM. Tautargeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011; 6: e26860.
149. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 2006; 5: 355-63.
150. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-97.
151. Ha D, Stone DK, Mosley L, Gendelman HE. Immunization strategies for Parkinson's disease. Parkinsonism Relat Disord 2012 Jan; 18 Suppl 1: S218-21.
152. Duke DC, Moran LB, Pearce RK, Graeber MB. The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics 2007; 8: 83-94.
153. Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 2007; 35: 1127-32.
154. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990; 39: 151-70.
155. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez- Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119: 182-92.
156. Reynolds AD, Stone DK, Mosley RL, Gendelman HE. Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol 2009; 182: 4137-49.
157. Reynolds AD, Stone DK, Mosley RL, Gendelman HE. Proteomic studies of nitrated alphasynuclein microglia regulation by CD4+CD25+ T cells. J Proteome Res 2009; 8: 3497-511.
158. Johnson LC, Su X, Maguire-Zeiss K, Horovitz K, Ankoudinova I, Guschin D, Hadaczek P, Federoff HJ, Bankiewicz K, Forsayeth J. Human Interleukin- 10 gene transfer is protective in a rat model of Parkinson's disease. Mol Ther 2008; 16: 1392-1399.
159. Quian L, Hong JS, Flood PM. Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of interleukin 10. J Neural Transm Suppl 2006; 70: 367-71.
160. Johnston LC, Su X, Maguire-Zeiss K, Horovitz K, Ankoudinova I, Guschin D, Hadaczek P, Federoff HJ, Bankiewicz K, Forsayeth J. Human Interleukin- 10 Gene Transfer Is Protective in a Rat Model of Parkinson's Disease. Mol Ther 2008; 16: 1392-1399.
161. Arimoto T, Choi DY, Lu X, Liu M, Nguyen XV, Zheng N, Stewart CA, Kim HC, Bing G. Interleukin- 10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging 2007; 28: 894-906.
162. Bolin LM, Strycharska-Orczyk I, Murray R, Langston JW, Di Monte D. Increased vulnerability of dopaminergic neurons in MPTP-lesioned inter-leukin-6 deficient mice. J Neurochem 2002; 83: 167-175.
163. Spittau B, Zhou X, Ming M, Krieglstein K. IL6 protects MN9D cells and midbrain dopaminergic neurons from MPP+-induced neurodegeneration. Neuromolecular Med 2012; 14: 317- 327.
164. Delgado M, Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson.s disease by blocking microglial activation. FASEB J 2003; 17: 944-6.
165. Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res 2000; 854: 257-62.
166. Chertoff M, Di Paolo N, Schoeneberg A, Depino A, Ferrari C, Wurst W, Pfizenmaier K, Eisel U, Pitossi F. Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice. Exp Neurol 2011; 227: 237-251.
167. Iczkiewicz J, Jackson MJ, Smith LA, Rose S, Jenner P. Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Res 2006; 1118: 239-50.
168. Iczkiewicz J, Rose S, Jenner P. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss. Exp Neurol 2007; 20: 95-106.
169. Maetzler W, Berg D, Schalamberidze N, Melms A, Schott K, Mueller JC, Liaw L, Gasser T, Nitsch C. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis 2007; 25: 473-482.
170. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol 2007; 82: 1083-1094.
171. Gendelman HE, Appel SH. Neuroprotective activities of regulatory T cells. Trends Mol Med 2011; 17: 687-688.
172. Reynolds AD, Stone DK, Hutter JAL, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 2010; 184: 2261-2271.
173. Scheeberger A, Mandler M, Mattner F, Schmidt W. Vaccination for Parkinson's disease. Parkinsonism Relat Disord 2012; 18: 11-13.
174. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M. Effects of alfa-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46: 857-868.
175. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D. Passive immunization reduces behavioral and neuropathological deficits in an al-pha-synuclein transgenic model of Lewy body disease. PLoS One 2011; 6: e19338.
176. Hutter-Saunders JAL, Lee Mosley R, Gendelman HE. Pathway towards an effective immunotherapy for Parkinson's disease. Expert Rev Neu-rother 2011; 11: 1703-1715.
177. Benner EJ, Mosley L, Destache C, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, Gendelman HE. Therapeuttic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2004; 101: 9435-40.
178. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007; 28: 639-647.
179. Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009; 26: 769-79.
180. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011; 76: 863-9.
181. Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012; 2: CD006378.
182. Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y. Non-steroidal antiinflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database Syst Rev 2011; 11: CD008454.